{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:03:31Z","timestamp":1792253011559,"version":"4.4.0"},"reference-count":41,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare, Japan","doi-asserted-by":"publisher","award":["H20-Junkanki-Ippan-016"],"award-info":[{"award-number":["H20-Junkanki-Ippan-016"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>The genotypes of vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) can influence therapeutic warfarin doses. Conversely, nongenetic factors, especially renal function, are associated with warfarin maintenance doses; however, the optimal algorithm for considering genes and renal dysfunction has not been established. This single-center prospective cohort study aimed to evaluate the factors affecting warfarin maintenance doses and develop pharmacogenetics-guided algorithms, including the factors of renal impairment and others. To commence, 176 outpatients who were prescribed warfarin for thromboembolic stroke prophylaxis in the stroke center, were enrolled. Patient characteristics, blood test results, dietary vitamin K intake, and CYP2C9 and VKORC1 (-1639G&gt;A) genotypes were recorded. CYP2C9 and VKORC1 (-1639G&gt;A) genotyping revealed that 80% of the patients had CYP2C9 *1\/*1 and VKORC1 mutant AA genotypes. Multiple linear regression analysis demonstrated that the optimal pharmacogenetics-based model comprised age, body surface area, estimated glomerular filtration rate (eGFR), genotypes, vitamin K intake, aspartate aminotransferase levels, and alcohol intake. eGFR exercised a significant impact on the maintenance doses, as an increase in eGFR of 10 mL\/min\/1.73 m2 escalated the warfarin maintenance dose by 0.6 mg. Reduced eGFR was related to lower warfarin maintenance doses, independent of VKORC1 and CYP2C9 genotypes in Japanese patients.<\/jats:p>","DOI":"10.3390\/genes12101537","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T12:29:14Z","timestamp":1632832154000},"page":"1537","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-236X","authenticated-orcid":false,"given":"Tomotaka","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Neurology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7102-4048","authenticated-orcid":false,"given":"Masafumi","family":"Ihara","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Fukuma","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Center for Advancing Clinical and Translational Sciences, National Cerebral and Cardiovascular Center, Suita, Osaka 564-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Washida","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kada","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Osaka 564-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka 564-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka 564-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Nagatsuka","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"243","article-title":"Warfarin pharmacogenomics","volume":"11","author":"Cavallari","year":"2009","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1160\/TH07-07-0454","article-title":"Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles","volume":"98","author":"Oldenburg","year":"2007","journal-title":"Thromb. Haemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1592\/phco.24.14.1311.43144","article-title":"Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin","volume":"24","author":"Wittkowsky","year":"2004","journal-title":"Pharmacotherapy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1160\/TH03-12-0741","article-title":"The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon","volume":"92","author":"Visser","year":"2004","journal-title":"Thromb. Haemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11239-007-0104-y","article-title":"Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues","volume":"25","author":"Gage","year":"2008","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","article-title":"CYP4F2 genetic variant alters required warfarin dose","volume":"111","author":"Caldwell","year":"2008","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/j.1538-7836.2007.02744.x","article-title":"Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose","volume":"5","author":"Rieder","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2710.2011.01314.x","article-title":"Clinically important drug-drug interactions in primary care","volume":"37","author":"Dhabali","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/bcp.14608","article-title":"Warfarin dosing algorithms: A systematic review","volume":"87","author":"Asiimwe","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2009-12-255992","article-title":"Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups","volume":"115","author":"Limdi","year":"2010","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2006.10.021","article-title":"Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives","volume":"120","author":"Yin","year":"2007","journal-title":"Thromb. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-007-0381-6","article-title":"Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: Proposal for a new dosing regimen in Chinese patients","volume":"63","author":"Miao","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2006.09.007","article-title":"Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients","volume":"120","author":"Kimura","year":"2007","journal-title":"Thromb. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/dmd.109.029991","article-title":"Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure","volume":"38","author":"Dani","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.2008070802","article-title":"Kidney function influences warfarin responsiveness and hemorrhagic complications","volume":"20","author":"Limdi","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00210-020-02037-3","article-title":"Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: Analysis from a randomized controlled trial","volume":"394","author":"Ning","year":"2021","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00508-018-1350-z","article-title":"Renal function in patients with mechanical prosthetic valves: Long-term effects of anticoagulation and over-anticoagulation with warfarin","volume":"130","author":"Canga","year":"2018","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11239-010-0459-3","article-title":"Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic","volume":"30","author":"Shaw","year":"2010","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_20","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","year":"1989","journal-title":"Nutrition"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2188\/jea.16.107","article-title":"Impact of the revision of a nutrient database on the validity of a self-administered food frequency questionnaire (FFQ)","volume":"16","author":"Ishihara","year":"2006","journal-title":"J. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00008571-199710000-00011","article-title":"Genetic analysis of CYP2C9 polymorphism in a Japanese population","volume":"7","author":"Nasu","year":"1997","journal-title":"Pharmacogenetics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.thromres.2010.05.016","article-title":"Application of Akaike information criterion to evaluate warfarin dosing algorithm","volume":"126","author":"Harada","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.STR.31.4.817","article-title":"Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: A multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group","volume":"31","author":"Yamaguchi","year":"2000","journal-title":"Stroke"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/000331970205300508","article-title":"Effects of anticoagulation on infarct size and clinical outcome in acute cardioembolic stroke","volume":"53","author":"Wakita","year":"2002","journal-title":"Angiology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.1365-2141.2003.04110.x","article-title":"Oral anticoagulants in the elderly","volume":"120","author":"Froom","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2008.10","article-title":"Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin","volume":"84","author":"Gage","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.ajkd.2010.05.023","article-title":"Warfarin dosing in patients with impaired kidney function","volume":"56","author":"Limdi","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/dmd.107.018192","article-title":"Effects of chronic renal failure on liver drug transporters","volume":"36","author":"Naud","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0009-9236(03)00015-8","article-title":"Cytochrome P4502C9 activity in end-stage renal disease","volume":"73","author":"Dreisbach","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/j.ackd.2010.05.009","article-title":"Nonrenal drug clearance in CKD: Searching for the path less traveled","volume":"17","author":"Momper","year":"2010","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1681\/ASN.2006010035","article-title":"Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure","volume":"17","author":"Michaud","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3109\/08860220903118608","article-title":"Acute kidney injury in patients with inactive cytochrome P450 polymorphisms","volume":"31","author":"Leung","year":"2009","journal-title":"Ren. Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1681\/ASN.2009070754","article-title":"Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation","volume":"20","author":"Genovesi","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1525-139X.2009.00632.x","article-title":"Use of warfarin in people with low glomerular filtration rate or on dialysis","volume":"22","author":"Holden","year":"2009","journal-title":"Semin. Dial."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1160\/TH08-03-0147","article-title":"Metabolism and cell biology of vitamin K","volume":"100","author":"Shearer","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jacc.2003.11.028","article-title":"Comparing the guidelines: Anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation","volume":"43","author":"Rockson","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s11239-008-0236-8","article-title":"Predictors of unstable anticoagulation in African Americans","volume":"27","author":"Cavallari","year":"2009","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1093\/hmg\/ddq389","article-title":"Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese","volume":"19","author":"Cha","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5761\/atcs.oa.10.01577","article-title":"Cystatin C in diabetics as a marker of mild renal insufficiency after CABG","volume":"17","author":"Jarvela","year":"2011","journal-title":"Ann. Thorac. Cardiovasc. Surg."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/10\/1537\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:06:38Z","timestamp":1760166398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/10\/1537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["genes12101537"],"URL":"https:\/\/doi.org\/10.3390\/genes12101537","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}